Latest News

March 29, 2017:

Phigenix receives Notice of Allowance of Israeli Patent Application #218286 entitled “Targeting PAX2 for the Treatment of Breast Cancer” covering its Antibody Drug Conjugate for the treatment of Breast Cancer.

 

January 9, 2017:

Phigenix receives Notice of Allowance of Israeli Patent Application #218285 entitled “Detecting PAX2 for the Diagnosis of Breast Cancer” covering its Diagnostic kit for monitoring Breast Conditions and determining a Treatment Regimen based on PAX2 to DEFB1 relative expression levels and ER, PR and HER2 status.

 

August 19, 2016:

Phigenix is awarded Japanese patent #P5990274 entitled “Targeting EN2, PAX2, and/or DEFB1 for the Treatment of Prostate Conditions” covering its EN2-, PAX2- and DEFB1-based Therapies and Companion Diagnostic for Prostate Cancer.

 

July  19, 2016:

Phigenix receives Notice of Allowance of Japanese Patent Application #P2014-54861 entitled “Targeting EN2, PAX2 and/or DEFB1-for Treatment of Prostate Conditions” covering its EN2-, PAX2- and DEFB1-based Therapies and Companion Diagnostic for Prostate Cancer.

 

July 14, 2016:

Phigenix is awarded Australian Patent #2009351638 entitled “Detecting PAX2 for the Diagnosis of Breast Cancer” covering its Diagnostic kit for Breast Cancer Detection.

 

January 22, 2016:

Phigenix receives notification of Intent to Grant Patent from the European Patent Office for patent application #10812443.9 entitled “Targeting PAX2 for the Treatment of Breast Cancer” covering its Breast Cancer Drugs.

 

February 2, 2015:

Phigenix receives Notice of Allowance of Korean patent application #10-2009-7011055 entitled “Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions” covering its Prostate Cancer Diagnostic kits.

 

January 14, 2015:

Phigenix is awarded Japanese patent #P5653042 entitled “Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions” covering its Prostate Cancer Diagnostic kits.

 

December 3, 2014:

Phigenix receives Notice of Decision to Grant from the African Regional Intellectual Property Organization for patent application #AP/P/2012/006181 entitled “Targeting PAX2 for the Treatment of Breast Cancer” covering its Breast Cancer Drugs and Companion Diagnostic kit.

 

December 3, 2014:

Phigenix receives Notice of Decision to Grant from the African Regional Intellectual Property Organization for patent application #AP/P/2012/006182  entitled “Detecting PAX2 for the Diagnosis of Breast Cancer” covering its Diagnostic kit for Breast Cancer Detection.

 

November 15, 2014:

Phigenix receives Notification to Grant Patent Rights for Chinese Patent Application #200980161426.2 entitled “Detecting PAX2 for the Diagnosis of Breast Cancer” covering its Diagnostic kit for Breast Cancer Detection.

 

November 10, 2014:

Phigenix receives Notice of Allowance of New Zealand patent application #599005 entitled “Targeting PAX2 for the Treatment of Breast Cancer” covering its Breast Cancer Drugs and Companion Diagnostic kit.

 

July 20, 2014:

Phigenix is awarded Russian Patent #2522485 entitled “Detecting PAX2 for the Diagnosis of Breast Cancer” covering its Diagnostic kit for Breast Cancer Detection.

 

May 27, 2014:

Phigenix is awarded US Patent #8,735,365 entitled “Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy” covering its Human Beta Defensin-1 based Prostate Cancer Therapeutics.

 

May 13, 2014:

Phigenix is awarded US Patent #8,722,367 entitled “Detecting PAX2 for the Diagnosis of Breast Cancer” covering its Diagnostic kit for Breast Cancer Detection.

 

May 13, 2014:

Phigenix is awarded US Patent #8,722,643 entitled “Targeting EN2, PAX2 and/or DEFB1-for Treatment of Prostate Conditions” covering its EN2-, PAX2- and DEFB1-based Therapies and Companion Diagnostic for Prostate Cancer.

 

April 28, 2014:

Phigenix receives Notice of Acceptance of New Zealand Patent #599004 entitled “Detecting PAX2 for the Diagnosis of Breast Cancer” covering its Diagnostic kit for Breast Cancer Detection.

 

April 25, 2014:

Phigenix is awarded Hong Kong patent #11108262.1 entitled “Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions” covering its Prostate Cancer Diagnostic kits and therapies.

March 4, 2014:

Phigenix is awarded New Zealand patent #596471 entitled “Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions” covering its Prostate Cancer therapies.

 

March 1, 2014:

Phigenix receives notification of Intent to Grant Patent from the European Patent Office for patent application #09848828 entitled “Detecting PAX2 for the Diagnosis of Breast Cancer” covering its Breast Cancer Diagnostic kit.

 

February 18, 2014:

Phigenix is awarded US Patent #8,653,021 entitled “Targeting PAX2 for the Treatment of Breast Cancer” covering its STAT3 inhibitors and Companion Diagnostic kit.

 

January 30, 2014:

Phigenix is awarded African Regional Intellectual Property Organization Patent #AP/P/2009/004851 entitled “Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions” covering its Prostate Cancer Diagnostic kits and therapies.

 

January 29, 2014:

Phigenix receives Notice of Allowance of US Patent Application #13/912,841 entitled “Targeting EN2, PAX2 and/or DEFB1-for Treatment of Prostate Conditions” covering its EN2-, PAX2- and DEFB1-based therapies and companion diagnostic for prostate cancer.

 

January 28, 2014:

Phigenix receives Notice of Allowance of US Patent Application #13/005,579 entitled “Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy” covering its Human Beta Defensin-1 (DEFB1)-based immunotherapy.

 

January 21, 2014:

Phigenix is awarded US Patent #8,633,149 entitled “Targeting PAX2 for the Treatment of Breast Cancer” covering its STAT3-based Breast Cancer Drugs and Companion Diagnostic Kit.

 

January 7, 2014:

Phigenix is awarded US Patent #8,623,617 entitled “Targeting PAX2 for the Diagnosis of Breast Cancer” covering its Breast Cancer Diagnostic kit for personalized medicine.

 

September 27, 2013:

Phigenix receives Notice of Allowance of US Patent Application #13/606,917 entitled “Targeting PAX2 for the Diagnosis of Breast Cancer” covering its Diagnostic kit for Breast Cancer detection.

 

August 07, 2013:

Phigenix is awarded Chinese Patent # ZL20088002349.1 entitled “Kits for Diagnosing Prostate Conditions“.

 

June 25, 2013:

Phigenix is awarded Israeli patent #198677 entitled “Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions” covering its Prostate Cancer Diagnostic kits and therapies.

 

June 11, 2013:

Phigenix is awarded US Patent #8,461,126 entitled “Targeting EN2, PAX2 and/or DEFB1-for Treatment of Prostate Conditions” covering its EN2-, PAX2- and DEFB1-based therapies for prostate cancer.

 

June 11, 2013:

Phigenix is awarded US Patent #8,461,101 entitled “Targeting PAX2 for the Treatment of Breast Cancer” covering its Breast Cancer Drugs and Companion Diagnostic kit.

 

June 4, 2013:

Phigenix is awarded Australian patent #2008206258 entitled “Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions” covering its Prostate Cancer Diagnostic kits and therapies.

 

May 21, 2013:

Phigenix is awarded US Patent #8,445,444 entitled “Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions” covering its Antibody-based Therapy for Pre-cancerous Prostate Intraepithelial Neoplasia (PIN).

 

April 30, 2013:

Phigenix is awarded US Patent # 8,431,546 entitled “Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy” covering Antisense-based Breast Cancer Therapeutics.

 

March 15, 2013:

Phigenix receives Notice of Acceptance in South Africa for Patent Application #2010/02474 entitled “Targeting PAX2 for the Treatment of Breast Cancer” covering its Breast Cancer Therapeutics.

 

March 12, 2013:

Phigenix is awarded US Patent #8,394,780 entitled “Targeting PAX2 for the Treatment of Breast Cancer” covering its Breast Cancer Drugs and Companion Diagnostic kit.

 

November 27, 2012:

Phigenix is awarded US Patent #8,318,692 entitled “Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy” covering oligonucleotide-based cancer therapies.

 

September 25, 2012:

Phigenix receives Notice of Acceptance in South Africa for Patent Application #2012/02170 entitled “Detecting PAX2 for the Diagnosis of Breast Cancer” covering its Breast Cancer Diagnostic kit.

 

September 18, 2012:

Phigenix receives Notice of Acceptance in Australian for patent #2006304321 entitled “Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy” covering small molecule-based prostate cancer therapies.

 

August 25, 2012:

Phigenix receives Notice of Acceptance in Australian for patent #2010286924 entitled “Targeting PAX2 for the Treatment of Breast Cancer” covering its Breast Cancer Drugs and Companion Diagnostic kit.

 

August 22, 2012:

Phigenix receives Notice of Allowance in the United States for US Patent Application #13/005,568 entitled “Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy” covering oligonucleotide-based cancer therapies.

 

April 19, 2012:

Phigenix receives notification from the European Patent Office that it will be granted  patent #2104744 entitled “Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions” covering its Prostate Cancer Diagnostic kit.

 

April 2, 2012:

Phigenix is awarded New Zealand patent #578164 entitled “Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions” covering its Prostate Cancer Diagnostic kit.

 

January 3, 2012:

Phigenix is awarded US Patent #8,088,603 entitled “Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions” covering its Prostate Cancer Diagnostic kit.

 

December 20, 2011:

Phigenix is awarded US Patent #8,080,534 entitled “Targeting PAX2 for the Treatment of Breast Cancer” covering its Breast Cancer Drugs and Companion Diagnostic kit.

 

October 26, 2011:

Phigenix receives Notice of Allowance in the United States for US Patent Application #12/708,294 entitled “Targeting PAX2 for the Treatment of Breast Cancer” covering its Breast Cancer Drugs and Companion Diagnostic kit.

 

October 18, 2011:

Phigenix receives Notice of Allowance in the United States for US Patent Application #12/440,193 entitled “Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions” covering its Prostate Cancer Diagnostic kit.

 

June 21, 2011:

Phigenix is awarded its first patent in the United States (US Patent # 7,964,577) entitled “Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy” covering small molecule-based prostate cancer therapies.

 

August 25, 2010:

Phigenix is awarded its first patent in South Africa (S. Africa Patent No. 2009/02814) entitled “Compositions and Methods for Diagnosing, Treating and Preventing Prostate Conditions”

 



      1. p.mp3